Intellia Therapeutics

Jenn King, Ph.D., SVP, Business Development
Cambridge, MA
(NASDAQ: NTLA)

Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of CRISPR/Cas9 technology and create a new class of therapeutic products. www.intelliatx.com